skip links
Andrew Davis
Senior Vice President, Chief Business Officer

Mr. Davis has served as our chief business officer since December 2021 and had served as senior vice president of corporate development, strategy and valuation from May 2021 to December 2021. Before joining Ironwood, Mr. Davis served as the chief business development and M&A officer at iNova Pharmaceuticals from September 2017 to May 2021, leading all company transactions and acting as a member of the executive management team. Prior to iNova, Mr. Davis was head of oncology business development for Merck & Co. from November 2016 to September 2017. Before his time at Merck, Mr. Davis was at Bausch Health Companies (formerly Valeant Pharmaceuticals), where he held roles of increasing responsibility within the business development function, ultimately serving as senior vice president of business development and leading all transactions for the company, including the acquisitions of Salix Pharmaceuticals and Bausch + Lomb. Mr. Davis began his career as an analyst at McKinsey & Co., where his work focused on the healthcare space. Mr. Davis serves on the board of directors of Biomarck Pharmaceuticals, Ltd. and UTILITY therapeutics Ltd. Mr. Davis holds a B.A. in economics from Boston University.